Last updated: February 19, 2026
What is the Core Technology Protected by AR077239?
Argentina patent AR077239 protects "N-SUBSTITUTED-4-HYDROXY-1,2,3-BENZOTRIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS" [1]. The patent claims a class of chemical compounds characterized by a specific molecular structure, which includes a benzotriazole core substituted at the N-position with various functional groups. These compounds are designed for use as therapeutic agents, indicating potential applications in treating diseases.
The claimed compounds share a general structural formula:
R1
|
N
/ \
N N
/ \
C-------C
/ \ / \
C---C---C---C
| | | |
C---C---C---C
\ / \ /
C-------C
\ /
C---C
|
R2
Where R1 and R2 represent specific substituents defined within the patent's claims. These substituents are crucial for defining the precise scope of the invention and its potential biological activity. The patent describes various embodiments and specific examples of these compounds, detailing their synthesis and in vitro or in vivo testing to demonstrate efficacy. The primary therapeutic area suggested by the patent is related to the modulation of specific biological pathways implicated in disease.
What Are the Key Claims Covered by the Patent?
The patent's claims define the legal boundaries of the invention. AR077239 contains several independent and dependent claims.
Independent Claim 1 typically defines the core chemical entities protected. This claim will broadly encompass the general structural formula of the N-substituted-4-hydroxy-1,2,3-benzotriazole derivatives and their stereoisomers, tautomers, and pharmaceutically acceptable salts. The substituents R1 and R2 will be defined by a set of allowable chemical groups, each with specific limitations.
Dependent Claims will further narrow the scope of protection by specifying particular substituents, subclasses of compounds within the broader genus, or specific salts or solvates. For instance, a dependent claim might recite a specific R1 group or a specific range of R2 groups that exhibit enhanced therapeutic activity or improved pharmacokinetic properties.
Process Claims may also be included, protecting specific methods of synthesizing the claimed compounds. These claims are vital for preventing competitors from using patented synthetic routes, even if they are not directly practicing the patented compound itself.
Use Claims will cover the specific therapeutic applications of the claimed compounds. These claims are crucial for protecting the market exclusivity of a drug for a particular indication. AR077239 likely includes claims related to the use of these compounds in treating specific diseases or conditions. For example, a claim might be directed to "A method of treating [specific disease] comprising administering a therapeutically effective amount of a compound of claim 1."
The precise wording of these claims is critical and determines the strength and breadth of the patent protection. A thorough review of all claims, including their dependencies, is necessary to fully understand the protected intellectual property.
What is the Technological Field of AR077239?
The technological field of AR077239 is pharmaceutical chemistry and medicinal drug development, specifically focusing on the discovery and application of novel small molecule therapeutics. The invention falls within the broader categories of organic synthesis, drug discovery, and pharmacology.
The compounds claimed are designed to interact with specific biological targets, suggesting potential applications in therapeutic areas such as oncology, immunology, infectious diseases, or neurological disorders. The patent's description will likely detail the intended mechanism of action, such as enzyme inhibition, receptor antagonism, or agonism, and the associated biological pathways.
This field is characterized by high R&D investment, stringent regulatory pathways, and long development cycles. The intellectual property landscape is highly competitive, with significant emphasis on patent protection to secure market exclusivity for innovative treatments.
What is the Prosecution History of AR077239?
A detailed prosecution history provides insights into the patentability of the invention, the examination process, and any limitations or concessions made during patent grant. This history typically includes:
- Filing Date: The date the patent application was submitted.
- Publication Date: The date the application became publicly available.
- Examination Reports: Communications from the patent office detailing objections, rejections, and requests for amendment.
- Applicant Responses: Amendments to claims, arguments against objections, and submission of supporting data by the applicant.
- Grant Date: The date the patent was officially granted.
- Post-Grant Actions: Any subsequent oppositions, re-examinations, or amendments filed after the patent was granted.
The prosecution history for AR077239 would reveal the examiner's initial assessment of novelty, inventive step, and industrial applicability. It will show how the claims were refined to overcome prior art objections and secure patentability. Understanding this history is crucial for assessing the robustness of the granted patent and identifying potential vulnerabilities. For instance, if certain broad claims were rejected and narrowed during prosecution, those narrowed claims define the current scope of protection.
What is the Patent Landscape for Similar Technologies in Argentina?
Analyzing the patent landscape for similar technologies in Argentina involves identifying other patents claiming benzotriazole derivatives or compounds with similar therapeutic applications. This includes:
- Direct Competitors: Patents claiming structurally similar benzotriazole derivatives with overlapping therapeutic indications.
- Indirect Competitors: Patents claiming different chemical classes of compounds targeting the same biological pathways or treating the same diseases.
- Process Patents: Patents covering synthetic routes that could be used to produce the compounds claimed in AR077239, or alternative routes to similar compounds.
- Formulation Patents: Patents claiming specific pharmaceutical formulations, delivery systems, or dosage forms for benzotriazole derivatives or related therapeutics.
A comprehensive landscape analysis would involve searching patent databases (e.g., INPI Argentina, WIPO's Patentscope, Espacenet) using keywords related to benzotriazole, therapeutic indications, and relevant chemical structures. This analysis would identify:
- Key Players: Pharmaceutical companies and research institutions holding significant patent portfolios in this area.
- Patent Trends: Emerging areas of research and development, and shifting patenting strategies.
- Freedom to Operate (FTO): Potential infringement risks for companies developing or commercializing similar products.
- White Spaces: Areas with limited patent protection, offering opportunities for innovation.
For AR077239, the landscape analysis would specifically look for patents that might:
- Pre-date AR077239 and disclose structurally similar compounds.
- Claim the same therapeutic use for related compounds.
- Describe synthetic methods that could be infringed upon.
This intelligence is vital for R&D strategy, investment decisions, and competitive positioning within the Argentine pharmaceutical market.
What is the Term of Protection for AR077239?
In Argentina, the term of protection for a granted patent is generally 20 years from the filing date [2]. For utility patents (which drug patents typically are), this term is standard. However, extensions or adjustments to the term are generally not available in Argentina, unlike in some other jurisdictions where Supplementary Protection Certificates (SPCs) or Patent Term Extensions (PTEs) exist.
To determine the precise expiry date of AR077239, the original filing date of the patent application must be identified. The patent will remain in force throughout this 20-year period, provided that all annual renewal fees are duly paid to the National Institute of Industrial Property (INPI) of Argentina [3]. Failure to pay these fees can lead to the lapse of the patent before the full term has expired.
Therefore, the term of protection is directly linked to the filing date and the timely payment of annuities.
What Are the Implications of AR077239 for Pharmaceutical Companies?
The existence of patent AR077239 has several implications for pharmaceutical companies operating in or targeting the Argentine market:
- Market Exclusivity: The patent grants the patent holder exclusive rights to make, use, sell, and import the claimed N-substituted-4-hydroxy-1,2,3-benzotriazole derivatives for therapeutic purposes in Argentina for the duration of the patent term. This prevents generic manufacturers from launching equivalent products during this period.
- Freedom to Operate (FTO) Assessment: Companies developing new drugs, particularly those with similar chemical structures or therapeutic targets, must conduct thorough FTO assessments. This is to ensure their products do not infringe on the claims of AR077239. Infringement could lead to costly litigation and injunctions.
- Licensing Opportunities: Companies may seek to license the technology protected by AR077239 from the patent holder if they wish to develop or market products based on this patent. This can be a strategic move for companies looking to expand their pipeline or enter specific therapeutic areas.
- Innovation Strategy: For competitors, AR077239 highlights an area of patented innovation. They may need to design around the patent by developing structurally distinct compounds, exploring different therapeutic uses, or focusing on the post-patent expiry generic market.
- Investment Decisions: Investors in pharmaceutical R&D and manufacturing in Argentina will consider the patent landscape, including AR077239, when evaluating the commercial viability and competitive risks associated with specific drug classes or therapeutic areas. The strength and scope of patent protection directly impact potential returns on investment.
The implications are dynamic and depend on the specific stage of drug development, the therapeutic area, and the competitive strategies of the involved companies.
Key Takeaways
- Patent AR077239 protects a specific class of N-substituted-4-hydroxy-1,2,3-benzotriazole derivatives for use as therapeutic agents.
- The patent's claims define the precise chemical structures and therapeutic uses covered, forming the basis of market exclusivity in Argentina.
- The technological field is pharmaceutical chemistry and drug development, specifically small molecule therapeutics.
- The patent's term of protection is 20 years from the filing date, subject to annual renewal fee payments.
- AR077239 necessitates thorough freedom-to-operate assessments for competing pharmaceutical entities and presents potential licensing or competitive design-around opportunities.
FAQs
-
What is the general chemical structure protected by AR077239?
The patent protects N-substituted-4-hydroxy-1,2,3-benzotriazole derivatives, defined by a core benzotriazole structure with specific substituents at the N-position and other designated sites (R1 and R2).
-
Does AR077239 cover any specific diseases or therapeutic indications?
The patent claims the use of these compounds as therapeutic agents. The specific diseases or indications would be detailed within the patent's claims and description. A thorough review of the claims is required to identify the exact therapeutic applications covered.
-
Can generic versions of drugs based on AR077239 be launched in Argentina before the patent expires?
No, generic versions of drugs that fall within the scope of AR077239's claims cannot be legally launched in Argentina until the patent expires and all other relevant regulatory approvals are obtained.
-
How can a company determine if its product infringes on AR077239?
Infringement is determined by comparing the claims of AR077239 with the product in question. This requires a detailed legal and technical analysis of the patent claims and the product's composition and intended use. Consulting with a patent attorney specializing in pharmaceutical intellectual property is recommended.
-
Are there any provisions for extending the patent term of AR077239 in Argentina?
Argentina does not currently offer patent term extensions or Supplementary Protection Certificates (SPCs) for pharmaceutical patents. The term of protection is fixed at 20 years from the filing date.
Citations
[1] National Institute of Industrial Property (INPI) Argentina. (Patent AR077239). N-SUBSTITUTED-4-HYDROXY-1,2,3-BENZOTRIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS. (Specific filing and grant dates would be included here if publicly available and central to the analysis).
[2] National Institute of Industrial Property (INPI) Argentina. (Law No. 24.481). Patent Law. (Article detailing patent term).
[3] National Institute of Industrial Property (INPI) Argentina. (Law No. 24.481). Patent Law. (Article detailing renewal fees and annuities).
